Literature DB >> 15682431

Is cannabis an anti-antipsychotic? The experience in psychiatric intensive care.

Maria Isaac1, Michael Isaac, Frank Holloway.   

Abstract

BACKGROUND: Cannabis use is a major problem in inner cities and has been causally implicated in psychosis. Very few of the available hospital-based studies of the implications of cannabis usage have involved psychiatric intensive care units (PICU); but PICU receive many of the most challenging and resource-hungry-and incompletely understood-patients in the mental health system. AIMS: To study the clinical impact of cannabis abuse in a PICU, and to compare the use of atypical and typical antipsychotics in this setting.
METHOD: 115 patients admitted to a PICU consented to take part in an open label naturalistic study. BPRS, TCI-240, weight, length of admission and routine bloods were evaluated in all participants.
RESULTS: There was a high rate of cannabis abuse (71.3%) in the PICU population. Patients who abused cannabis spent longer in PICU because their psychoses were more severe. They were younger at first hospital admission. Cannabis also had metabolic implications, with higher blood glucose levels at admission and greater weight increase. Atypical antipsychotics were effective in treating psychosis inpatients positive to cannabis at admission.
CONCLUSION: Our findings suggest that cannabis abusers had a more severe psychotic illness, especially in schizophrenia. There are additional complications in terms of weight gain for cannabis users. Copyright (c) 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15682431     DOI: 10.1002/hup.674

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  6 in total

Review 1.  Variations in rates of comorbid substance use in psychosis between mental health settings and geographical areas in the UK. A systematic review.

Authors:  Giuseppe Carrà; Sonia Johnson
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-11-13       Impact factor: 4.328

2.  Cannabis use and metabolic syndrome among clients with first episode psychosis.

Authors:  Erik Stiles; Karl C Alcover; Bryan Stiles; Oladunni Oluwoye; Michael G McDonell
Journal:  Early Interv Psychiatry       Date:  2020-09-02       Impact factor: 2.732

Review 3.  Developing therapeutics for schizophrenia and other psychotic disorders.

Authors:  Gerard Marek; Kalpana Merchant
Journal:  NeuroRx       Date:  2005-10

Review 4.  Marijuana Use in the Era of Changing Cannabis Laws: What Are the Risks? Who is Most at Risk?

Authors:  William V Stoecker; Emily E Rapp; Joseph M Malters
Journal:  Mo Med       Date:  2018 Sep-Oct

5.  Behavioral interventions for antipsychotic induced appetite changes.

Authors:  Ursula Werneke; David Taylor; Thomas A B Sanders
Journal:  Curr Psychiatry Rep       Date:  2013-03       Impact factor: 5.285

6.  Improving physical health and reducing substance use in psychosis--randomised control trial (IMPACT RCT): study protocol for a cluster randomised controlled trial.

Authors:  Fiona Gaughran; Daniel Stahl; Khalida Ismail; Zerrin Atakan; John Lally; Poonam Gardner-Sood; Anita Patel; Anthony David; David Hopkins; Bee Harries; Philippa Lowe; Diana Orr; Maurice Arbuthnot; Robin M Murray; Kathryn E Greenwood; Shubulade Smith
Journal:  BMC Psychiatry       Date:  2013-10-16       Impact factor: 3.630

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.